Cargando…

Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities

SIMPLE SUMMARY: Oncogenic KRAS signaling drives several effector cascades that contribute not only to the malignant behavior of pancreatic cancer cells but also formation of the fibro-inflammatory microenvironment. The non-neoplastic cells in the tumor microenvironment interact with tumor cells, cre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bansod, Sapana, Dodhiawala, Paarth B., Lim, Kian-Huat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582583/ https://www.ncbi.nlm.nih.gov/pubmed/34771644 http://dx.doi.org/10.3390/cancers13215481

Ejemplares similares

Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer
por: Khurana, Namrata, et al.
Publicado: (2020)

Phospho-Ser(784)-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor
por: Wang, Faliang, et al.
Publicado: (2021)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Kras as a key oncogene and therapeutic target in pancreatic cancer
por: Collins, Meredith A., et al.
Publicado: (2014)

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
por: Kamerkar, Sushrut, et al.
Publicado: (2017)

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels
por: Kong, Bo, et al.
Publicado: (2013)

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
por: Kang, R, et al.
Publicado: (2014)

Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model
por: Bansod, Sapana, et al.
Publicado: (2021)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
por: Santana-Codina, Naiara, et al.
Publicado: (2018)

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
por: Kim, Dongsung, et al.
Publicado: (2023)

Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities
por: Dricu, Anica
Publicado: (2022)

Loss of Jag1 cooperates with oncogenic Kras to induce pancreatic cystic neoplasms
por: Chung, Wen-Cheng, et al.
Publicado: (2020)

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
por: Dai, Manxiong, et al.
Publicado: (2022)

Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer
por: Wang, Yanzhao, et al.
Publicado: (2015)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
por: Bulle, Ashenafi, et al.
Publicado: (2020)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
por: Learte-Aymamí, Soraya, et al.
Publicado: (2022)

Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications
por: Ferreira, Anabela, et al.
Publicado: (2022)

Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis
por: Sivakumar, Shivan, et al.
Publicado: (2017)

The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice
por: Young, Claire C., et al.
Publicado: (2018)

USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
por: Hou, Pingping, et al.
Publicado: (2021)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
por: Cheng, Derek K., et al.
Publicado: (2021)

Acute Pancreatitis Accelerates Initiation and Progression to Pancreatic Cancer in Mice Expressing Oncogenic Kras in the Nestin Cell Lineage
por: Carrière, Catherine, et al.
Publicado: (2011)

Pancreatitis promotes oncogenic Kras(G12D)-induced pancreatic transformation through activation of Nupr1
por: Grasso, Daniel, et al.
Publicado: (2014)

Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects
por: Polani, Faran, et al.
Publicado: (2021)

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
por: Vallejo, Adrian, et al.
Publicado: (2017)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022)

COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives
por: Saifi, Mohd Aslam, et al.
Publicado: (2022)

Pancreatic cancer survival analysis defines a signature that predicts outcome
por: Raman, Pichai, et al.
Publicado: (2018)

An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer
por: Kent, Oliver A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_54ch65v8gq298a188370t3plc1